Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.

Wan Uk Kim, So Youn Min, Mi La Cho, Kyung Hee Hong, Yong Joo Shin, Sung Hwan Park, Chul Soo Cho

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of cancer, autoimmune disease, and various pathologic conditions characterized by excessive fibrosis. In this study, we investigated the expression of MMP-9 and its clinical significance in systemic sclerosis (SSc). The patients (n = 42) with SSc had higher concentrations of MMP-9 and of tissue inhibitor of metalloproteinase-1 (TIMP-1) and a higher ratio of MMP-9 to TIMP-1 in sera than healthy controls (n = 32). Serum MMP-9 concentrations were significantly higher in the diffuse type (n = 23) than the limited type of SSc (n = 19). Serum concentrations of MMP-9 correlated well with the degree of skin involvement, as determined by the Rodnan score and with serum concentrations of transforming growth factor beta. Moreover, dermal fibroblasts from patients with SSc produced more MMP-9 than those from healthy controls when they were stimulated with IL-1beta, tumor necrosis factor alpha, or transforming growth factor beta. Such an increase in MMP-9 production was partially blocked by treatment with cyclosporin A. In summary, the serum MMP-9 concentrations were elevated in SSc patients and correlated well with skin scores. The increased MMP-9 concentrations may be attributable to overproduction by dermal fibroblasts in SSc. These findings suggest that the enhanced production of MMP-9 may contribute to fibrogenic remodeling during the progression of skin sclerosis in SSc.

Original languageEnglish (US)
JournalArthritis research & therapy
Volume7
Issue number1
StatePublished - 2005

Fingerprint

Systemic Scleroderma
Matrix Metalloproteinase 9
Skin
Serum
Tissue Inhibitor of Metalloproteinase-1
Transforming Growth Factor beta
Fibroblasts
Sclerosis
Cyclosporine
Autoimmune Diseases
Fibrosis
Tumor Necrosis Factor-alpha

Cite this

Kim, W. U., Min, S. Y., Cho, M. L., Hong, K. H., Shin, Y. J., Park, S. H., & Cho, C. S. (2005). Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis research & therapy, 7(1).

Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. / Kim, Wan Uk; Min, So Youn; Cho, Mi La; Hong, Kyung Hee; Shin, Yong Joo; Park, Sung Hwan; Cho, Chul Soo.

In: Arthritis research & therapy, Vol. 7, No. 1, 2005.

Research output: Contribution to journalArticle

Kim, WU, Min, SY, Cho, ML, Hong, KH, Shin, YJ, Park, SH & Cho, CS 2005, 'Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.', Arthritis research & therapy, vol. 7, no. 1.
Kim, Wan Uk ; Min, So Youn ; Cho, Mi La ; Hong, Kyung Hee ; Shin, Yong Joo ; Park, Sung Hwan ; Cho, Chul Soo. / Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. In: Arthritis research & therapy. 2005 ; Vol. 7, No. 1.
@article{bf276620fd0346ada79397f799f442aa,
title = "Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.",
abstract = "Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of cancer, autoimmune disease, and various pathologic conditions characterized by excessive fibrosis. In this study, we investigated the expression of MMP-9 and its clinical significance in systemic sclerosis (SSc). The patients (n = 42) with SSc had higher concentrations of MMP-9 and of tissue inhibitor of metalloproteinase-1 (TIMP-1) and a higher ratio of MMP-9 to TIMP-1 in sera than healthy controls (n = 32). Serum MMP-9 concentrations were significantly higher in the diffuse type (n = 23) than the limited type of SSc (n = 19). Serum concentrations of MMP-9 correlated well with the degree of skin involvement, as determined by the Rodnan score and with serum concentrations of transforming growth factor beta. Moreover, dermal fibroblasts from patients with SSc produced more MMP-9 than those from healthy controls when they were stimulated with IL-1beta, tumor necrosis factor alpha, or transforming growth factor beta. Such an increase in MMP-9 production was partially blocked by treatment with cyclosporin A. In summary, the serum MMP-9 concentrations were elevated in SSc patients and correlated well with skin scores. The increased MMP-9 concentrations may be attributable to overproduction by dermal fibroblasts in SSc. These findings suggest that the enhanced production of MMP-9 may contribute to fibrogenic remodeling during the progression of skin sclerosis in SSc.",
author = "Kim, {Wan Uk} and Min, {So Youn} and Cho, {Mi La} and Hong, {Kyung Hee} and Shin, {Yong Joo} and Park, {Sung Hwan} and Cho, {Chul Soo}",
year = "2005",
language = "English (US)",
volume = "7",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Elevated matrix metalloproteinase-9 in patients with systemic sclerosis.

AU - Kim, Wan Uk

AU - Min, So Youn

AU - Cho, Mi La

AU - Hong, Kyung Hee

AU - Shin, Yong Joo

AU - Park, Sung Hwan

AU - Cho, Chul Soo

PY - 2005

Y1 - 2005

N2 - Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of cancer, autoimmune disease, and various pathologic conditions characterized by excessive fibrosis. In this study, we investigated the expression of MMP-9 and its clinical significance in systemic sclerosis (SSc). The patients (n = 42) with SSc had higher concentrations of MMP-9 and of tissue inhibitor of metalloproteinase-1 (TIMP-1) and a higher ratio of MMP-9 to TIMP-1 in sera than healthy controls (n = 32). Serum MMP-9 concentrations were significantly higher in the diffuse type (n = 23) than the limited type of SSc (n = 19). Serum concentrations of MMP-9 correlated well with the degree of skin involvement, as determined by the Rodnan score and with serum concentrations of transforming growth factor beta. Moreover, dermal fibroblasts from patients with SSc produced more MMP-9 than those from healthy controls when they were stimulated with IL-1beta, tumor necrosis factor alpha, or transforming growth factor beta. Such an increase in MMP-9 production was partially blocked by treatment with cyclosporin A. In summary, the serum MMP-9 concentrations were elevated in SSc patients and correlated well with skin scores. The increased MMP-9 concentrations may be attributable to overproduction by dermal fibroblasts in SSc. These findings suggest that the enhanced production of MMP-9 may contribute to fibrogenic remodeling during the progression of skin sclerosis in SSc.

AB - Matrix metalloproteinase-9 (MMP-9) has been implicated in the pathogenesis of cancer, autoimmune disease, and various pathologic conditions characterized by excessive fibrosis. In this study, we investigated the expression of MMP-9 and its clinical significance in systemic sclerosis (SSc). The patients (n = 42) with SSc had higher concentrations of MMP-9 and of tissue inhibitor of metalloproteinase-1 (TIMP-1) and a higher ratio of MMP-9 to TIMP-1 in sera than healthy controls (n = 32). Serum MMP-9 concentrations were significantly higher in the diffuse type (n = 23) than the limited type of SSc (n = 19). Serum concentrations of MMP-9 correlated well with the degree of skin involvement, as determined by the Rodnan score and with serum concentrations of transforming growth factor beta. Moreover, dermal fibroblasts from patients with SSc produced more MMP-9 than those from healthy controls when they were stimulated with IL-1beta, tumor necrosis factor alpha, or transforming growth factor beta. Such an increase in MMP-9 production was partially blocked by treatment with cyclosporin A. In summary, the serum MMP-9 concentrations were elevated in SSc patients and correlated well with skin scores. The increased MMP-9 concentrations may be attributable to overproduction by dermal fibroblasts in SSc. These findings suggest that the enhanced production of MMP-9 may contribute to fibrogenic remodeling during the progression of skin sclerosis in SSc.

UR - http://www.scopus.com/inward/record.url?scp=28244481204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244481204&partnerID=8YFLogxK

M3 - Article

C2 - 15642145

AN - SCOPUS:28244481204

VL - 7

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

ER -